Endocr Pract. 2023 May 22. pii: S1530-891X(23)00414-7. [Epub ahead of print]
OBJECTIVE: Hyperandrogenism is frequently observed in patients with polycystic ovary (PCOS). The purpose of this study was to develop an easy-to-use tool for predicting polycystic ovary syndrome (PCOS) and to evaluate and compare the value of androstenedione (Andro) and other hormone indicators in the diagnosis of patients with hyperandrogenic PCOS.METHODS: This study included 139 women diagnosed with hyperandrogenic PCOS according to the Rotterdam criteria and 74 healthy control women from Shanghai Tenth People's Hospital. The serum hormone levels of the patients and controls were measured using a chemiluminescence immunoassay (CLIA) and incorporated for further analysis.
RESULTS: Total testosterone (TT), Andro, Dehydroepiandrosterone sulfate (DHEAS), and Free androgen index (FAI) were significantly higher in the PCOS group than the control group. Further, Andro, FSH, LH, TT, FAI and LH/FSH in the hyper-androstenedione (HA) group were higher than the normal Andro (NA) group. The Youden index was the highest for Andro (0.65), with 81.82% sensitivity and 83.16% specificity. Correlation analysis showed that FSH, LH, TT, FAI, Insulin Sensitivity Index (ISI), and LH/FSH were positively correlated with Andro, while Fasting blood glucose (FPG) and two-hour postprandial blood glucose (2h PG) were negatively correlated with Andro.
CONCLUSIONS: The model using Andro, TT, FAI may help to identifying women with undiagnosed PCOS. Serum Andro is a meaningful biomarker for hyperandrogenism in PCOS patients and may further aid disease diagnosis.
Keywords: PCOS; androstenedione; diagnostic; hyperandrogenism; steroid hormones